<DOC>
	<DOCNO>NCT00005980</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know regimen liposomal doxorubicin effective metastatic breast cancer . PURPOSE : Randomized phase II trial compare effectiveness two regimen liposomal doxorubicin treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Comparison Two Regimens Liposomal Doxorubicin Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate woman metastatic breast cancer treat two different dose schedule doxorubicin HCL liposome . - Assess side effect treatment regimens patient population . - Determine duration response patient treat regimen . - Assess concentration doxorubicin tumor tissue patient easily accessible metastasis . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , performance status ( 0-1 v 2 ) , visceral disease ( yes v ) , available lesion biopsy ( yes v ) , prior adjuvant anthracyclines ( yes v ) , prior chemotherapy advance disease ( yes v ) . Patients randomize one two treatment arm . - Arm I : Patients receive doxorubicin HCL liposome IV 1 hour every 6 week . - Arm II : Patients receive doxorubicin HCL liposome IV 1 hour every 4 week . Treatment continue least 36 week absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 64-100 patient ( 32-50 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven progressive recurrent metastatic breast cancer Bidimensionally measurable disease least one target lesion If previously irradiate lesion : No preirradiated lesion Clear progression prior study New lesion previously irradiate region allow Refusal medical contraindication standard anthracycline contain regimen Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Any age Sex : Female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal Transaminases le 2 time upper limit normal Renal : Creatinine normal Cardiovascular : Left ventricular ejection fraction normal echocardiography MUGA scan No significant cardiac history include : Clinically significant atrial ventricular arrhythmia require treatment Medically control congestive heart failure Significant angina clinically and/or electrocardiographically document myocardial infarction within past year Clinically significant valvular disease Other : No prior concurrent malignancy within past 5 year except contralateral breast cancer , adequately treat basal cell skin cancer carcinoma situ cervix No psychological , familial , sociological , geographical condition would preclude study Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Prior adjuvant chemotherapy allow total doxorubicin dose great 300 mg/m2 , total epirubicin dose great 450 mg/m^2 , total mitoxantrone dose great 75 mg/m^2 No great one regimen prior chemotherapy metastatic disease No prior anthracyclines metastatic disease No concurrent cytotoxic therapy Endocrine therapy : No concurrent hormonal therapy At least 4 week since prior progestin , estrogen , androgens Radiotherapy : See Disease Characteristics Concurrent palliative radiotherapy allow sole target lesion outside irradiated field Surgery : Not specify Other : Concurrent bisphosphonates metastatic bone disease hypercalcemia secondary malignancy allow bony lesion target lesion No concurrent investigational therapy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>